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Background: The optimal surgical technique for lobectomy in lung cancer is not well defined. Proponents of
video-assisted thoracic surgery (VATS) hypothesize that less trauma leads to quicker recovery, whereas those
who advocate thoracotomy claim it as an oncologically superior procedure. However, a well-balanced compar-
ison of the two procedures is lacking in the literature.
Methods:All patients who underwent lobectomy for clinical stage 1A lung cancer by computed tomographic and
positron emission tomographic scan were identified from a prospective database. Patient characteristics were
compared by the Student t test, Pearson c2, and Fisher exact test. A propensity score–matched analysis was per-
formed. Survival was assessed by Kaplan–Meier and Cox proportional hazards analysis. Complications were as-
sessed by a multivariate logistic regression model evaluating age, sex, comorbidities, pulmonary function, tumor
size, nodal status, surgeon, and histologic characteristics.
Results: From May 2002 to August 2007, 398 patients underwent an attempt at VATS lobectomy and 343 un-
derwent thoracotomy. An ‘‘intent-to-treat’’ analysis was performed. There was 1 postoperative death in each
group. Survival by Cox model was no different for VATS versus thoracotomy (hazard ratio 0.72; P ¼ .12),
whereas age (hazard ratio 1.03; P<.001), larger tumor size (hazard ratio 1.34; P<.001), and higher nodal stage
(hazard ratio 1.92; P< .001) were associated with worse survival. Logistic regression demonstrated fewer com-
plications for VATS lobectomy (odds ratio 0.73; P¼ .06), whereas age (odds ratio 1.04; P<.001) and tumor size
(odds ratio 1.2; P< .020) correlated with a greater number of complications. Patients undergoing VATS lobec-
tomy demonstrated a 2-day shorter length of stay than patients undergoing thoracotomy (P< .001). Propensity
score–matched analysis supported these findings.
Conclusions:VATS lobectomy and thoracotomy demonstrated similar 5-year survivals. However, VATS lobec-
tomy was associated with fewer complications and shorter length of hospital stay.Earn CME credits at
http://cme.ctsnetjournals.org
The role of VATS wedge resection for the diagnosis of lung
cancer is well established whereas the role of VATS lobec-
tomy for treatment is not well defined.Many case series have
demonstrated the feasibility of VATS lobectomy since it was
first described in the early 1990s; however, surgeons have
been reticent to use the technique because of intraoperative
safety and long-term oncologic concerns.1 The Society of
Thoracic Surgeons database demonstrates that only 16%
of lobectomies reported in the United States are performed
by the VATS method.2
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literature are scarce. The majority of data is low on the
evidence-based scale and the studies are often underpow-
ered.3 Recently, the demand in our practice for VATS lobec-
tomy appears to be driven by patients and to a lesser extent
by resident trainees. The obvious arguments in favor of
VATS lobectomy include cosmesis, less postoperative
pain, shorter length of stay, and lower overall cost, but there
is a paucity of evidence-based data to support these assump-
tions. At present, no well-balanced comparative studies of
sufficient power exist to adequately compare VATS lobec-
tomy with thoracotomy lobectomy.
Therefore, we undertook this study to evaluate whether
VATS lobectomy could be performed by a uniform tech-
nique among different surgeons with acceptable short- and
long-term outcomes when compared with standard thoracot-
omy on a homogeneous well-balanced large population
from a single institution.
METHODS
Data Aquisition
All patients with clinical stage IA non–small cell lung cancer by com-
puted tomographic (CT) and positron emission tomographic (PET) scan
were identified from a prospectively maintained institutional thoracic data-
base after institutional review board approval. Excluded patients included
those with a history of preoperative chemotherapy; histologic diagnosis ofCardiovascular Surgery c Volume 138, Number 1 11
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CT ¼ computed tomography
DLCO ¼ diffusing capacity for carbon monoxide
FEV1 ¼ forced expiratory volume in 1 second
PET ¼ positron emission tomography
benign disease, carcinoid, small cell, or mucoepidermoid carcinoma; proce-
dures other than a lobectomy, such as wedge, segmentectomy, bilobectomy,
pneumonectomy, or chest wall resection; and those with multiple primary
tumors.
Variables recorded included age, sex, comorbidities, pulmonary func-
tion, tumor size, nodal status, and histologic characteristics. Comorbidities
included coronary artery disease, valvular heart disease, dysrhythmia, hy-
pertension, chronic obstructive pulmonary disease, asthma, renal insuffi-
ciency, and diabetes mellitus. Smoking history was defined as current
(any amount), former (>100 cigarettes in a lifetime), and never (0–100 cig-
arettes in a lifetime) smokers.
All complications were graded according to the National Cancer Institute
Common Terminology Criteria for Adverse Events version 3.0 (http://ctep.
cancer.gov/reporting/ctc.html). Survival was recorded from day of the oper-
ation until date of death or last follow-up. Deaths were verified by the Social
Security Death Index. Perioperative mortality was defined as death within
30 days of the operation or within the same hospital admission.
Operative Technique
The decision to perform either procedure wasmade by the individual sur-
geon. Four surgeons (R.F., V.R., B.P., and N.R.) perform VATS lobectomy
for patients with early-stage disease whereas two surgeons (R.D. and M.B.)
exclusively perform thoracotomy lobectomy for such patients.
All patients underwent standard anesthesia care with the use of double-
lumen endotracheal tubes and perioperative fluid restriction. Postoperative
pain relief was provided by continuous epidural administration of fentanyl
and bupivacaine and/or intravenous opioid administration.
TABLE 1. Patient characteristics
VATS
(n ¼ 398, 54%)
Thoracotomy
(n ¼ 343, 46%)
P
value
Age, y (mean) 67 (36–90) 67 (35–89) .59
Male sex 152 (38) 117 (34) .25
No. of comorbidities
1 178 (45) 167 (49) .43
2 66 (17) 57 (17)
3 8 (2) 11 (3)
4 1 2
FEV1 (%) 92 88 .01
DLCO (%) 90 84 .004
Smoking history
Current 57 (14) 53 (15) .77
Former 288 (72) 240 (70)
Never 53 (13) 50 (15)
COPD 88 (22) 105 (30) .01
Cardiac disease 201 (50) 177 (52) .07
Diabetes mellitus 44 (11) 38 (11) .42
Chronic renal
insufficiency
6 (2) 2 (1) .31
VATS, Video-assisted thoracic surgery; FEV1, Forced expiratory volume in 1 second;
DLCO, diffusing capacity for carbon monoxide; COPD, chronic obstructive pulmo-
nary disease. Figures in parentheses indicate either range or percent.12 The Journal of Thoracic and Cardiovascular SurgVATS lobectomy was performed via a 4-cm utility incision at the ante-
rior axillary line at the third or fourth intercostal space by using standard tho-
racic instruments without rib spreading, a 2-cm anterior thoracostomy port
at the eighth intercostal space at the anterior axillary line for the camera, and
a 2-cm posterior port for retraction and stapler insertion. The operation was
performed entirely with thoracoscopic visualization. The hilar structures
were individually ligated by endovascular staplers, and mediastinal nodal
dissection or sampling was performed. The camera port was subsequently
used as a thoracostomy tube site. Our technique has been described previ-
ously.4,5 In VATS cases in which the robot was used for assistance in dis-
section, the same three VATS incisions were used as described in an
earlier report.6
Thoracotomy lobectomy was performed via a posterolateral thoracot-
omy incision that spared the serratus anterior muscle. The chest was entered
via the fifth intercostal space and a Finochietto retractor was used to gain
exposure. Endoscopic staplers were routinely used for the transection of
vessels and the completion of the fissures. In all patients an ipsilateral me-
diastinal dissection or sampling was performed.
Statistical Methods
Patient characteristics and perioperative data were compared by the Stu-
dent t test, Pearson c2, and Fisher’s exact test. Survival was assessed by
Kaplan–Meier and Cox proportional hazards analysis. Conversions from
VATS to thoracotomy were analyzed in the VATS cohort by the ‘‘intent-
to-treat’’ method. Complications were assessed by a multivariate logistic
TABLE 2. Perioperative data
VATS
(n ¼ 398)
Thoracotomy
(n ¼ 343)
P
value
Pathologic stage
IA 260 (65) 213 (62) .49
IB 69 (17) 62 (18)
IIA 19 (5) 17 (5)
IIB 12 (3) 15 (4)
IIIA 29 (7) 21 (6)
IIIB 9 (2) 15 (4)
Histology
Adenocarcinoma 159 (40) 122 (36) .1
Adenocarcinoma w/BAC 179 (45) 145 (42)
BAC 6 (2) 12 (3)
Squamous 44 (11) 56 (16)
Large cell 10 (3) 8 (2)
Tumor location
LLL 44 (11) 53 (15) .196
LUL 115 (29) 86 (25)
RLL 52 (13) 54 (16)
RML 21 (5) 23 (7)
RUL 166 (42) 127 (37)
Tumor size, cm (mean) 2 2 .55
No. of nodal
stations removed
3.6 4.5 <.0001
Complications (any) 96 (24) 104 (30) .05
LOS (d) 5 7 <.0001
Deaths 1 1
Median OR time (h) 3:40 3:44
Conversions 70 (17)
VATS, Video-assisted thoracic surgery; BAC, bronchoalveolar carcinoma; LLL, left
lower lobe; LUL, left upper lobe; RLL, right lower lobe; RML, right middle lobe;
RUL, right upper lobe; LOS, length of stay;OR, operating room. Figures in parentheses
indicate percent.ery c July 2009
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tumor size, nodal status, surgeon, and histologic characteristics; nonsignif-
icant variables were excluded in a stepwise fashion to obtain the final model.
STATA 10 software (Stata Corporation, College Station, TX) was used to
perform statistical analyses.
A propensity score–matched analysis was performed. Propensity scores
were generated for all patients eligible to undergo either VATS or thoracot-
omy lobectomy. VATS versus thoracotomy was the treatment indicator
(dependent variable) and the covariates were age, sex, comorbidities, forced
expiratory volume in 1 second (FEV1), diffusing capacity for carbon mon-
oxide (DLCO), smoking history, stage, histologic characteristics, tumor
size, and nodal status. Nearest neighbor matching method was used without
replacement. VATS and thoracotomy group covariates were compared by
standardized differences. Patients were stratified by propensity score group-
ings to evaluate survival, complications, and length of stay among the
VATS and thoracotomy groups. Cox and logistic regression models were
constructed to evaluate the influence of VATS on survival and complica-
tions, respectively, adjusting for propensity score. STATA 10/ PSMATCH2
(Leuven and Sianesi) was used to perform statistical analyses.
RESULTS
From 2002 to 2007, 741 patients with clinically staged IA
non–small cell lung cancer underwent surgical resection. Of
these, 343 underwent thoracotomy and 398 underwent at-
tempted VATS lobectomy, of whom 70 required conver-
sions to thoracotomy. There was one perioperative death
in each group and there were no intraoperative deaths. Me-
dian follow-up was 28 months in both groups. Patient char-
acteristics and perioperative findings are shown in Tables 1
and 2, respectively.
Of the 64 procedures that were begun as VATS with ro-
botic assistance, 59 were completed by VATS and 5 were
TABLE 3. Reasons for conversion from VATS to thoracotomy
No. Percent
Tumor location 22 6
Adhesions 15 4
Bleeding 11 3
Adenopathy 9 2
Anatomy 8 2
Failed lung isolation 4 1
Obesity 1
Total 70
TABLE 4A. Complications by CTCAE: VATS lobectomy group
Grade
Complication 1 2 3 4 5
Atrial arrhythmia 41
Hemorrhage 5
Gastrointestinal 2 1
Respiratory 26 1 1
Empyema
Prolonged air leak 17
Pulmonary embolus 3
Myocardial infarction 1
Other 4
CTCAE, Common Terminology Criteria for Adverse Events.The Journal of Thoracic andconverted to thoracotomy. Conversions are outlined in Table 3.
A total of 102 adverse events occurred in 96 patients in the
VATS group and 123 in the 104 patients undergoing tho-
racotomy. Eight patients in the VATS group and 13 in the
thoracotomy group had grade 3 or higher complications
(Tables 4A and 4B).
Kaplan–Meier analysis demonstrated a 79% 5-year sur-
vival for the VATS group and a 75% 5-year survival for
the thoracotomy group (log rank; P ¼ .08) (Figure 1). A
Cox proportional hazards model included age, sex, comor-
bidities, pulmonary function tests, smoking history, tumor
location, surgeon, type of surgical procedure, histologic
type, tumor size, and nodal status. Stepwise elimination
of insignificant variables yielded the final model shown
in Table 5A. The multivariate analyses demonstrated
increased age, tumor size, and nodal stage to adversely af-
fect outcome. The intent-to-treat analysis, which included
conversions in the thoracotomy group, demonstrated a haz-
ard ratio of 0.72 for the VATS group (P ¼ .12). When all
three groups were analyzed separately (VATS, thoracot-
omy, and conversion groups), no significant differences
TABLE 4B. Complications by CTCAE: Thoracotomy lobectomy
group
Grade
Complication 1 2 3 4 5
Atrial arrhythmia 43
Hemorrhage 2
Gastrointestinal 2 1
Respiratory 34 6 1 1
Empyema 1
Prolonged air leak 18
Pulmonary embolus 2
Myocardial infarction 2
Other 2 6 2
CTCAE, Common Terminology Criteria for Adverse Events.
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FIGURE 1. VATS versus thoracotomy. Intent to treat. VATS,Video-assis-
ted thoracic surgery; CI, confidence intervals.Cardiovascular Surgery c Volume 138, Number 1 13
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analysis. When the conversion group was placed in the
thoracotomy group, the survival was no different by Ka-
plan–Meier analysis (P ¼ .07). When the Cox model in-
cluded the conversions in the thoracotomy group, the
hazard ratio for VATS lobectomy dropped to 0.67 (P ¼
.08, confidence intervals 0.43, 1.05).
A logistic regression model was created yielding the final
model shown in Table 5B. Increased age and tumor size
were significant predictors of complications. VATS lobec-
tomy appeared to yield fewer complications (odds ratio ¼
0.73; P ¼ .06) when controlling for tumor size and age.
The conversion coefficient in the regression model demon-
strated a value of 0.3 (P ¼ .27), which was equal and oppo-
site to the sign of the coefficient of VATS of0.3 (P ¼ .06).
When conversions were included in the thoracotomy group,
ignoring the intent-to-treat principle, the VATS lobectomy
odds ratio was 0.64 (P ¼ .01; highly significant).
An interaction term of age and tumor size was generated
and assessed in both Cox and logistic regression models.
The term was insignificant, suggesting no evidence of inter-
action between the two variables.
The two groups were well balanced with regard to stage.
This was the main reason for performing the analysis by the
intent-to-treat method. We wanted patients with more com-
plicated disease, and (theoretically) a greater tendency for
complications and longer lengths of hospital stay, to be in-
cluded in the VATS lobectomy group. However, the
TABLE 5A. Cox proportional hazards model of all 741 patients
HR CI P value
VATS 0.72 0.47, 1.1 .12
Age 1.03 1.01, 1.06 <.001
Tumor size 1.34 1.15, 1.62 <.001
Nodal stage 1.92 1.47, 2.52 <.001
HR,Hazard ratio; CI, confidence intervals; VATS, video-assisted thoracic surgery. His-
tology, surgeon, comorbidities, sex, and smoking history were not significant.14 The Journal of Thoracic and Cardiovascular Surgconversion group demonstrated a similar stage distribution
when compared with the VATS and thoracotomy groups:
stage IA, 47 patients; stage IB, 8 patients; stage IIA, 2
patients; stage IIB, 3 patients; stage IIIA, 8 patients; and
stage IIIB, 2 patients.
A propensity score–matched analysis was performed.
Propensity scores were generated for 677 patients; 64 of
741 patients did not receive a propensity score owing to
missing variables. After propensity score matching, 51 un-
matched patients were excluded, yielding a total of 313
patients in each of the VATS and thoracotomy groups. Co-
variates were compared by standardized differences (Table
6). Patients were then grouped by propensity scores, which
demonstrated similar survival between the VATS and thora-
cotomy groups but fewer complications and a shorter length
of stay for the VATS group (Table 7). Propensity scores
were then multiplied by 10 to present hazard ratios in terms
of a 10% change in propensity score. A Cox proportional
hazards model demonstrated a hazard ratio of 0.8 for the
VATS group when adjusted for propensity score (Table
8A). A logistic regression model with complication as the
dependent variable demonstrated an odds ratio of 0.67 for
the VATS group when adjusted for propensity score
(Table 8B).
DISCUSSION
The technique of VATS lobectomy has developed during
the past two decades, with most data presented in the form of
TABLE 5B. Logistic regression: Complications as the dependent
variable of all 741 patients
OR CI P value
VATS 0.73 0.52, 1.01 .06
Age 1.04 1.02, 1.06 <.001
Tumor size 1.2 1.02, 1.40 .02
OR,Odds ratio; CI, confidence intervals; VATS, video-assisted thoracic surgery. Histol-
ogy, surgeon, comorbidities, sex, smoking history, and nodal stage were not significant.TABLE 6. Comparison of baseline characteristics of raw, propensity score–matched, and –unmatched data
Raw data Propensity score matching Unmatched (n ¼ 115)
VATS
(n ¼ 398)
Thoracotomy
(n ¼ 343)
Standardized
difference*
VATS
(n ¼ 313)
Thoracotomy
(n ¼ 313)
Standardized
difference*
VATS (n ¼ 85);
thoracotomy
(n ¼ 30)
Age 67 68 10 67 68 10 72
Male sex 152 (38%) 117 (34%) 4 129 (41%) 106 (34%) 7 35 (30%)
No comorbidities 145 (36%) 106 (31%) 5 128 (41%) 95 (30%) 12 28 (24%)
FEV1 (% predicted) 92 88 17 95 88 31 73
DLCO (% predicted) 90 84 21 93 84 31 70
Never smokers 53 (13%) 50 (14%) 0.01 36 (12%) 47 (15%) 4 20 (17%)
Greater than stage 1 69 (17%) 68 (20%) 4 47 (15%) 63 (20%) 6 26 (23%)
Non-adenocarcinoma histology 54 (14%) 64 (19%) 7 24 (8%) 59 (19%) 16 35 (30%)
Tumor size (cm) 2 2 4 2 2.1 10 2.4
Nodal disease 64 (16%) 55 (16%) 0.3 47 (15%) 50 (16%) 3 21 (18%)
VATS, Video-assisted thoracic surgery; FEV1, forced expiratory volume in 1 second; DLCO, diffusing capacity of carbon monoxide. *Standardized difference is the mean differ-
ence divided by the pooled SD, expressed as a percentage.ery c July 2009
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<0.4 .04–0.59 >0.6
VATS (n) 20 232 112
Thoracotomy (n) 42 212 59
Survival (VATS HR, CI, P value) 0.9, CI (0.27, 2.99), P ¼ .9 0.9, CI (0.55, 1.6), P ¼ .8 0.5, CI (0.15, 1.7), P ¼ .27
Complications (VATS, Thor, P value) 0.6, 0.4, P ¼ .1 0.23, 0.33, P ¼.03 0.16, 0.19, P ¼ .67
LOS, d (VATS, Thor, P value) 9, 8, P ¼ .3 5, 7, P< .0001 4, 6, P ¼ .01
VATS, Video-assisted thoracic surgery; HR, hazard ratio; CI, confidence intervals; Thor, thoracotomy; LOS, length of stay.large case series that focus on the feasibility of this ap-
proach.1,3,7-10 However, these large series tend to favor
VATS lobectomy inasmuch as they do not provide adequate
thoracotomy comparison groups and may inadvertently ex-
clude conversions of VATS to thoracotomy. A major prob-
lem in comparing VATS lobectomy from one study with
thoracotomy survival from other studies is that populations
may differ significantly with regard to patient tumor histo-
logic types, sex, and stage. Such factors influence survival
results and can mask any differences related to surgical tech-
nique. The theoretical advantages of decreased pain, shorter
length of stay, better pulmonary function, and preservation
of host immunity should lead to improved short- and long-
term outcomes. However, VATS lobectomy must be sup-
ported by solid data if it is to gain greater acceptance in
mainstream thoracic surgery practice.
Current published data comparing VATS with thoracot-
omy consist of a few underpowered randomized controlled
trials. The quality and sample size of these studies do not
permit statistically valid conclusions.11-14 One of the largest
retrospective comparative studies from Watanabe and asso-
ciates,15 which included more than 100 patients in each
group, was imbalanced because of a greater number of T2
lesions in the thoracotomy patient group.
In addition, the vast majority of comparative studies fail to
adhere to the intention-to-treat principle, a major design flaw
that would inherently bias results in favor of VATS lobec-
tomy. Indeed, many comparative studies demonstrate a sur-
vival benefit in favor of VATS lobectomy that is frequently
attributed to better outcome from less chest wall trauma.16-18
However, it is more likely that the thoracotomy group in-
cludes converted cases that are likely to be higher stage
and more technically difficult then those performed by
VATS.
Published conversion rates from VATS to thoracotomy
range from 1.6% to 19%.1,3,8,9 These results may be inaccu-
rate because of retrospective data acquisition. Our study
benefits from routine prospective data collections performed
TABLE 8A. Cox proportional hazards model of 626 propensity score–
matched patients
HR CI P value
VATS 0.8 0.27, 1.3 .4
Propensity score 0.68 0.52, 0.88 .004
VATS, Video-assisted thoracic surgery; HR, hazard ratio; CI, confidence intervals.The Journal of Thoracic andweekly by our group with review by the involved surgical
attending staff. Indications for VATS lobectomy as well as
thresholds for conversions vary among surgeons, and these
factors change over time as the surgeon gains more experi-
ence with the procedure.
Our cohort of patients was well balanced in all categories
between the thoracotomy and VATS lobectomy groups,
therefore minimizing bias from known confounders. Preop-
erative comorbidities were similar. Although more patients
were labeled as having chronic obstructive pulmonary dis-
ease in the thoracotomy group, smoking history was similar
and preoperative FEV1 and DLCO differed between the two
groups by only 4% and 6%, respectively. The thoracotomy
group had a mean of one extranodal station sampled; how-
ever, there were no significant differences in stage distribu-
tion or overall survival. Nodal evaluation is dependent on
effort and surgeon and is not due to any technical limitation
of VATS. For example, when operating on upper lobe tu-
mors by VATS, we rarely take down the inferior pulmonary
ligament and dissect out the level 9 nodes, thus reducing the
total number of nodal stations sampled by one. However, the
value of such additional sampling is debatable inasmuch as
level 9 nodal metastases are rare for upper lobe tumors.
The propensity score–matched analysis supported the
results of the raw data. Survival among the different pro-
pensity score groupings demonstrated similar survival
between VATS and thoracotomy groups and fewer
complications and shorter length of stay for the VATS
group.
This study also demonstrates that thoracotomy for lung
cancer can be performedwith an excellent outcome. Interest-
ingly, conversion from VATS to thoracotomy does not ap-
pear to pose an increased risk of complications other than
those associated with thoracotomy alone. Conversion in
the regression model is an interaction term because only pa-
tients undergoing VATS can be converted. The regression
coefficient of VATS (0.3) was equal and opposite in sign
to that of patients converted from VATS to thoracotomy
TABLE 8B. Logistic regression model of 626 propensity score–
matched patients (dependent variable ¼ complications)
OR CI P value
VATS 0.67 0.45, 0.98 .04
Propensity score 0.71 0.57, 0.87 .001
VATS, Video-assisted thoracic surgery; OR, odds ratio; CI, confidence intervals.Cardiovascular Surgery c Volume 138, Number 1 15
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VATS to thoracotomy were the same as for primary thora-
cotomy. The small difference in complication rate and low
operative mortality underscores the effectiveness of lobec-
tomy by thoracotomy even after conversion; therefore, any
VATS case in which oncologic principles may be compro-
mised should be converted to thoracotomy.
Limitations of the Study
Every study has limitations. Our data lack narcotic infor-
mation, a validated pain scale, and an objective measure-
ment of postoperative pulmonary function. Although the
data in this study were gathered prospectively, the analysis
was performed retrospectively; therefore, unknown con-
founding variables and inherent selection biases could exist.
The comparisons in this study are inextricably confounded
with systematic surgeon selection bias: 100% of the
VATS lobectomies are performed by four surgeons whereas
two of the surgeons only perform thoracotomy. Thus, com-
plications may be based on unrecorded surgeon-related fac-
tors that cannot be separated from those intrinsic to the
approach. However, given the experience and the expertise
of the two surgeons performing thoracotomy, we believe
this is unlikely.
A randomized controlled trial is considered to be the gold
standard to demonstrate superiority of one procedure over
another, but it may not be feasible in many situations. How-
ever, an adequately powered randomized controlled trial on
this topic is unlikely because many VATS surgeons are un-
willing to randomize patients and many patients tend to seek
out surgeons who are willing to perform this procedure.
On the basis of the presented data, VATS lobectomy and
thoracotomy are both acceptable procedures for the treat-
ment of lung cancer and are associated with similar long-
term survivals. However, VATS lobectomy is associated
with fewer complications and a significantly decreased
length of hospital stay. Nevertheless, the performance of
an oncologically sound operation must take priority over
a suboptimal VATS lobectomy, and conversion to thoracot-
omy should be performed in situations in which the extent of
disease mandates an open procedure for complete resection.
We thank Robert McKenna for allowing one author (R.F.) to ob-
serve his operative technique. We also thank Colin Begg for lend-
ing his expertise in biostatistics to review this study.
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Discussion
Dr Scott J. Swanson (New York, NY). Dr Flores, you are to be
congratulated for an excellent report regarding an important topic in
lung cancer. Your results are quite impressive.
I would like to highlight a couple of pertinent facts and then ask
three questions. Your database shows that 90% of patients have ad-
enocarcinoma and most are women, consistent with the clear-cut
change in epidemiology we have all witnessed over the past 20
years. However, approximately 15% of your cohort are never
smokers, a trend that is clearly on the rise, very disturbing, and
argues for a critical need for translational research funding in this
area. It appears that your clinical staging system based on CT and
PET was only accurate in about two thirds of the population. Fully
33% to 40% were understaged, and that has been seen elsewhere in
the 2008 meeting of The American Association for Thoracic Sur-
gery. Approximately 10% of your patients were found to have stage
III disease. About 18% of your patients in the VATS lobectomyery c July 2009
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Flores et al General Thoracic Surgerygroup were converted to thoracotomy. My first question pertains to
the last point. Why do you think your conversion rate is higher than
most? Ours is approximately 5%. We also use a prospective data-
base. What does tumor location mean, as 22 patients were con-
verted on this basis, and this is in the setting of a mean tumor
size of 2 cm? My point about this is that your survival difference
between VATS and thoracotomy borders on significance at .08.
In fact, if you showed that slide in an oncology meeting, that would
be a highly significant slide. If your conversion rate was lower, per-
haps you would have seen a significant difference in survival.
Dr Flores. That is a good point about the conversion rate. It is
the central point of this presentation. Most of the data out there
are retrospective. I think retrospective analyses tend to miss the
conversion patients. The most common reasons that patients are
converted are theoretically higher stage, adhesions, ambiguous
anatomy, and other such findings. Including such patients in the
thoracotomy group will skew the results in favor of VATS lobec-
tomy; therefore, we adhered to the intent-to-treat principle and in-
cluded them in the VATS lobectomy group, which would in theory
make the VATS group look worse. Since you mentioned oncology
meetings, this is the standard methodology for an oncologic study.
I think our results are pretty consistent with the prospective data,
because theCALGB (Cancer andLeukemiaGroupB) trial, inwhich
you were an investigator, had a 14% conversion rate. That study in-
cluded surgeons who had substantial experience in performing
VATS lobectomy and did not include their learning curves. There-
fore, I think the conversion rate of 14% in that series is more realistic
for experienced VATS lobectomy surgeons rather than the lower
conversion rates reported in the case series literature. In our study,
four different surgeons were performingVATS lobectomy. Also in-
cluded within our reported conversion rate is our learning curve, so
that includes the learning curve conversions of all four surgeons. I
think it is an honest way of reporting the results. Even though it is
a retrospective analysis, these data are gathered prospectively.
Dr Swanson. You might look at survival without the intention-
to-treat principle.
Dr Flores. Survival without intention-to-treat data shows that
VATS lobectomy is highly significant and superior to thoracotomy,
and I do not think that is an appropriate analysis. Manywould argue
the bias would favor VATS lobectomy.
Dr Swanson.My second question pertains to lymph nodes. I as-
sume none of these patients had mediastinoscopies, but about 10%
had stage III disease. Do you think it is important to identify these
patients before resection? If so, have you considered doing what we
do—performing an initial ipsilateral mediastinal node evaluation
using VATS before resection and, if positive, stopping and giving
induction therapy before coming back for lobectomy? The morbid-
ity of this approach is not higher than that of mediastinoscopy and
allows for chemotherapy or chemoradiation to start within a week.
Also of importance, it does not add time to the operation. We have
also found that a similar percentage of patients, 5% to 10%, will
have positive results. Do you know how this 10% cohort fared in
terms of survival? I assume they all received adjuvant therapy.
Finally, in the same vein, do you have a standard approach for
sampling lymph nodes? Do you think it is important to harvest
the same number of nodes or nodal stations no matter what the
approach? As you point out in this paper, about one less station
was sampled in VATS than in thoracotomy.The Journal of Thoracic andDr Flores. Those are good points.
I have pondered the question about doing a nodal dissection first
and then giving induction therapy, and I think you will find vari-
ability among the surgeons in our institution. The new data that
have been reported in the medical oncology literature indicate
that adjuvant chemotherapy is beneficial. That said, when stage
IIIAmicroscopic nodal disease is identified, after a thorough preop-
erative staging with CT, magnetic resonance imaging, and PET, I
fail to see why stopping the operation and giving the patient induc-
tion therapy is better than just doing a nodal dissection and admin-
istering postoperative chemotherapy.
From the nodal standpoint, we routinely perform the same nodal
dissection sampling with VATS as we do with open thoracotomy.
One case scenario is different—and since we had a preponderance
of upper lobectomies, I think this is where the decrease among
nodal stations takes place. When we have a left upper lobe or right
upper lobe, we do not mobilize the inferior pulmonary ligament and
we do not take the level 9 lymph node. I think that is where that
number difference comes from.
Dr Swanson.My last question pertains to your overall survival
and outcome. I do think you should study the pain and functional
issues, because these may be key differences between these two
approaches if the survival differences that are being suggested
are difficult to prove. We have recently published an article show-
ing pain is minimal at 2 weeks and that adjuvant chemotherapy can
be delivered at full dose and on time in over 70% of patients under-
going a VATS approach. Why do you think that you had such ex-
cellent survival when almost 20% of your patients had stage II or
stage III disease? You had about an 80% long-term survival, which
seems very good. What methods of follow-up do you use to get
your survival figures? Do you depend on the Social Security Death
Index to determine whether a patient is alive or dead, or do you do
chart follow-up or telephone calls?
Dr Flores. Our primary method of survival is through our insti-
tution. The institution monitors these patients closely, and we have
a set of data managers who follow up with that. In addition, we look
at the Social Security Death Index. However, there is a 6-month lag
period with the Social Security Death Index, so that alone is not suf-
ficient when you are evaluating our time period.
Dr Todd L. Demmy (Buffalo, NY). An index of the maturity of
a VATS lobectomy program is the proportion of total lobes that you
are doing thoracoscopically. Do you have the percentage in this
time period that were done thoracoscopically?
Dr Flores. No, I do not have that number.
Dr Demmy. Your FEV1 is in the 80% to 90% range, which sug-
gests that this is a very selective population of patients with good
pulmonary function. That tends to lead to better collapse of the
lung and a somewhat technically easier VATS lobectomy. Could
you comment on that? Since your study has found fewer complica-
tions, are you going to now offer VATS lobectomy to the high-risk
group in which you expect more complications?
Dr Flores. The FEV1 point reported is the mean FEV1. The
range goes down as far as 40% of predicted with FEV1 and
DLCO, so the number that you are looking at is the mean. I did
not provide the range. However, I think the important point of
this paper is that the patients were selected in the same way. The
thoracotomy patients and the VATS patients were selected on the
basis of the CT scan, PET scan, and pulmonary function tests.Cardiovascular Surgery c Volume 138, Number 1 17
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tomies at our institution.
Dr Erino A. Rendina (Rome, Italy).When comparing thoracot-
omy with VATS lobectomy, I think it is very important to also give
the details about the thoracotomy. It is very important to know
whether you are comparing VATS with a small thoracotomy of
maybe 9 or 10 cm or with the sternovertebral thoracotomy of our
ancestors. Obviously, that might have an impact on the postopera-
tive course.
Dr Flores. Absolutely. I think that is a great point, and that is
always my argument. It is discussed in the manuscript. All of these
patients had division of the latissimus dorsi, sparing the serratus an-
terior muscle; the hilar ligation was usually performed with staples,
and the fissure was completed with staples as well.
Dr DavidM. Follette (Sacramento, Calif).Dr Flores, we do not
really know that patients with microscopic stage IIIA disease do
better than the neoadjuvant group. In fact, there is a Southwest On-
cology Group (SWOG) trial looking at that with radiation. That is
a presumption based on the data we have for adjuvant treatment.
My question for you is this: inasmuch as your boss is one of the
leaders and proponents of neoadjuvant treatment, what is your abil-
ity to give neoadjuvant treatment in terms of patient compliance
versus adjuvant treatment in a similar group of patients? That is
the important question. At Sloan–Kettering, do you see as large
a difference as all the rest of us do in your ability to give neoadju-
vant versus adjuvant chemotherapy?
Dr Flores. Sure.That is the biggest argumentwith induction ther-
apy. You can get more chemotherapy into the patient and complete
the cycles giving induction. In cases of obvious stage IIIA disease,
we will do mediastinoscopy and try to identify it. We do give induc-
tion therapy as well. However, I always teachmy fellows that not all
stage IIIA disease is same. They stratify by number of nodal stations
involved, microscopic versus bulky nodal disease, and so on. I think
the patients with stage IIIA disease in the VATS lobe cohort are go-
ing to havemicroscopic disease, usually at a single stationwhen pre-
screened by CT and PET. There is no right answer. So, the operation
has begun. The patient is under general anesthesia. I would remove
the diseased lobe and lymph nodes and administer adjuvant therapy.
However, I do understand the controversy that exists.
Dr David J. Sugarbaker (Boston, Mass). I have just a brief
comment on that. We do not need to reinvent or go back to the fu-
ture. Induction therapy for stage IIIA disease in two randomized tri-
als gives superior survival. Adjuvant chemotherapy in stage IIIA
disease, according to Cybulski and some of the other large reports
of resected micrometastatic disease, gives 5% to 12% 5-year sur-
vival. So even the CALGB trial, which is now being published
and of which I am an author, suggests that there is no difference
in earlier stage disease between those getting adjuvant therapy
and those not. The data for adjuvant chemotherapy in the treatment
of stage IIIA disease, whether it be microscopic or not, is inconclu-
sive in terms of its effect on survival. The only data we have that are18 The Journal of Thoracic and Cardiovascular Surprospective from both the Roth trial and the Roselle trial indicate
that a large difference in survival is seen with induction treatment.
Dr Flores.No, I completely disagree with you on that point. You
are quoting antiquated studies published 15 years ago that include
patients enrolledwell before that. The Roselle trial and the induction
trials involved about 100 patients as opposed to the recent adjuvant
trials, which involved thousands of patients, and the subset of
patients with stage IIIA disease did better with adjuvant therapy
than the patients who did not get adjuvant therapy. The numbers
you are quoting are very small. I do not agree with your point.
Dr Sugarbaker. Well, Dr Flores, which trial are you talking
about?
Dr Flores. The one from France.
Dr Sugarbaker. Who is the author? I do not recall that one.
Dr Flores. There have been numerous prospective studies:
ALPI, ANITA, BLT, JBR10, and the LACE meta-analysis, which
showed that patients with stage III disease had a hazard ratio of 0.83
with adjuvant therapy. However, the initial one that I was referring
to was the LeChevallier study, the International Adjuvant Lung
Cancer Trial (IALT), the big one from France that was presented
at the American Society of Clinical Oncology meeting, which res-
urrected adjuvant therapy in lung cancer.
Dr Sugarbaker. That study was underpowered in stage IIIA dis-
ease.
Dr Mark J. Krasna (Towson, Md). Dr Flores, I will disagree
with you on that point. I want to agree with Dr Sugarbaker. There
are actually two studies and they are both retrospective. I think one
was from MD Anderson almost a decade ago and the other was
from Italy. They actually looked at the subpopulation that you
are talking about, patients in whom you open the chest, find residual
disease, and then go back in after they have received a full dose of
neoadjuvant therapy. Thus there are some data, although not pro-
spective. But, again, if you take the subset that Dr Sugarbaker is
talking about, which I agree is good prospective data, and you
take these other subsets of patients whom you actually close, treat
neoadjuvantly, and then resect, I actually agree; I think those pa-
tients should be offered the best possible therapy, which is neoad-
juvant.
Dr Flores.Well, I guess I have to beat this horse dead although I
think this discussion is beyond the scope of this paper. However, to
complete my argument, those two trials, the MD Anderson one and
the Roselle trial, were performed well before the lung cancer stag-
ing system revisions in 1997. They included patients who had T3
N0 lesions that initially were staged as IIIA but have been now
downstaged to stage II because of improved survival. Although
those older studies are stage IIIA, by today’s standards they include
stage II disease as well and therefore are inherently flawed, in addi-
tion to having very few patients. That is a different subset of inho-
mogeneous patients, not the microscopic single station nodal
disease that we speak about today in stage IIIA lung cancer with
VATS lobectomy.gery c July 2009
